Evidence map›Paper›PMID 35756848›Full record

ReviewImmuno-oncology technology2019

Sprayable gel for postsurgical immunotherapy.

Qian Chen, Tianyuan Ci, Zhen Gu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immuno-oncology technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Advances in engineering local drug delivery systems for cancer immunotherapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020
    Review
  4. Getting visible with exciting IO tech!Immuno-oncology technology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Qian ChenInstitute of Functional Nano and Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Jiangsu, PR China.
Tianyuan CiDepartment of Bioengineering, University of California, Los Angeles, USA.
Zhen GuDepartment of Bioengineering, University of California, Los Angeles, USA.
California NanoSystems Institute · USUniversity of California, Los Angeles · USUniversity of Colorado Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Surgery remains the first option to treat most solid tumors. However, despite the development of surgical techniques, the elimination of tumor recurrence after surgery remains a challenge. Design: In a recent study published in Conclusion: The engineered immunotherapeutic gel could activate both innate and adaptive immune responses systemically after local treatment, effectively destroying the remaining cancer cells and reducing tumor recurrence.

Indexed as

Cancer immunotherapyLocal treatmentSurgeryTumor recurrence

Identifiers

PMID35756848
PMCPMC9216252
OpenAlexW2965859723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.